Nephrology Conferences
Advertisement
Healthcare professionals who have made significant contributions to the field of kidney disease will be honored at SCM25.
Dietitian Lauren Budd Levy explains the importance of renal nutrition and related sessions at NKF SKM25.
Can SZC help with RAASi maximization without resultant hyperkalemia in patients with HFrEF and CKD?
Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months.
Current eligibility criteria for simultaneous heart and kidney transplantation may be subject to eGFRcr errors.
How accurately and efficiently does artificial intelligence perform clinical prescreening compared with nephrologists?
The WRAPSODY stent may help restore circuit patency when stenosis or occlusion occurs within the AVG or AVF for hemodialysis.
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
Zigakibart for treatment of IgA nephropathy (IgAN) was well tolerated, reduced proteinuria, and stabilized eGFR at 76 weeks.
A clinical trial examined the relationship between steroid exposure and bone mineral density changes in children.
An analysis sought to determine the economic costs of treating SARS-CoV-2 infection among kidney transplant recipients.
The International Society of Nephrology (ISN) has announced the 2025 recipients of the ISN Awards and ISN Pioneer Awards.
Obinutuzumab reduced proteinuria in patients with FSGS who were treatment-resistant or on immunosuppressive therapy.
RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD?
A study examined the efficacy of adding SZC to allow patients with stage 3-4 DKD to maintain treatment with RAASi.
Researchers assessed the safety and efficacy of bardoxolone methyl (BARD) in patients with ADPKD.
Vlado Perkovic spoke about findings from the FLOW, APPLAUSE-IgAN, and CREDENCE trials presented at ASN Kidney Week.
Researchers studied the efficacy and safety of dapagliflozin in patients with chronic kidney disease stages 4 and 5.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.